Celltrion Pharm Presents Research Results on Two Dual Payload ADC Candidates at 'AACR 2026'

Celltrion Pharm announced on April 24 that it participated in the American Association for Cancer Research (AACR 2026), held in San Diego, United States, from April 17 to April 22 (local time), where it presented research results on two new pipeline candidates based on its dual payload antibody-drug conjugate (ADC) platform.

Celltrion Pharm Presents Research Results on Two Types of ADC Dual Payloads at AACR 2026. Celltrion Pharm

At AACR 2025 last year, Celltrion Pharm unveiled its dual payload ADC platform for the first time by introducing the HER2-targeted candidate 'CTPH-02', which combines two different payloads with distinct mechanisms of action onto a single antibody. This platform demonstrated strong cytotoxicity with high synergy not only in cell lines with high HER2 expression but also in those with low expression levels, thereby confirming the platform’s technological potential.

This year, Celltrion Pharm expanded the scope of the platform and clarified the direction for further development by announcing follow-up research achievements for the TROP2 (Trophoblast Cell Surface Antigen 2) targeting 'CTPH-03' and the folate receptor alpha (FRα) targeting 'CTPH-08'.

The newly announced CTPH-03 is a dual payload ADC candidate that targets the TROP2 protein expressed in cancer cells. By combining a new payload with an existing cytotoxic anticancer agent, it maximized anticancer efficacy and demonstrated excellent toxicity evaluation results at the non-clinical stage, securing a stable therapeutic index (TI).

Also announced was 'CTPH-08', a dual payload ADC candidate targeting FRα, representing the application of platform technologies accumulated from the development of CTPH-02 and CTPH-03 to a new target. This not only demonstrated the scalability of the dual payload technology but also attracted academic attention by suggesting the potential to overcome 'tumor heterogeneity' and 'drug resistance', which have been pointed out as limitations of existing ADCs.

Based on this announcement, Celltrion Pharm plans to accelerate the advancement of its dual payload ADC platform. In addition to the currently developed tubulin binder series, the company is pursuing the development of new payloads and aims to further enhance platform competitiveness by incorporating site-specific conjugation technology. Furthermore, it plans to continue additional preclinical evaluations of CTPH-03 and CTPH-08.

In addition, Celltrion Pharm aims to increase the flexibility and scalability of candidate molecule design by combining Celltrion’s antibody-based technological capabilities with Celltrion Pharm’s linker-payload diversification and chemistry-based platform development expertise.

A Celltrion Pharm representative said, “This announcement proves that Celltrion Pharm’s proprietary dual payload platform has strong scalability that can be applied to various targets beyond specific antigens. We will do our utmost to secure differentiated competitiveness in the next-generation ADC drug market by combining Celltrion’s unrivaled antibody technology with Celltrion Pharm’s linker-payload development capabilities.”

This content was produced with the assistance of AI translation services.